Dr. Shah Discusses Autologous Transplant in MCL

Video

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Not all patients with MCL in first remission should receive ASCT, says Shah. The main alternative would be rituximab (Rituxan) maintenance therapy, but there is not yet enough information on duration of treatment with this approach.

Shah says, at this point, it is up to the patient to either undergo transplant or rituximab maintenance.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD